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INTRODUCTION
Hepatitis C (HCV) is a bloodborne virus. 
Acute infection is usually asymptomatic, with 
symptoms not appearing until after several 
years of chronic infection, when the liver may 
be severely damaged, leading to patients 
presenting late with cirrhosis and liver 
disease.1 In the UK, injecting drug use is the 
main route of HCV transmission; other routes 
include unscreened blood transfusion, unsafe 
health care, exposure to blood-contaminated 
needles, for example, by tattooing, and sexual 
practices that lead to exposure to blood.1,2 
Research from 2019 suggests that up to 
43% of future hepatitis C infections could 
be prevented if transmission among people 
who inject drugs was reduced.3 Treatment 
of chronic HCV infection results in sustained 
viral clearance in a high percentage 
(>95%) of treated patients.4 An estimated 
143 000 people in the UK have chronic HCV 
infection;2,5 however, HCV has been described 
as a silent epidemic, with <50% of those 
infected aware of their HCV status and with 
many more not receiving treatment, who 
are therefore at increased risk of morbidity, 
mortality, and onward transmission.2,5,6 HCV 
screening interventions have been effective in 
increasing case finding in target populations, 
for example, in migrants and attenders at 
drug treatment centres;7,8 however, those 
not in contact with specialist services are 
not systematically being assessed. The 
crucial role of primary care in stemming the 
HCV epidemic and preventing HCV-related 
illness has been highlighted,9 although many 
primary care patients at risk of HCV infection 
have not been tested.10 
The World Health Organization (WHO) has 
called for an increase in HCV diagnosis, setting 
a target of 90% of infected people in Europe 
knowing their status by 2030.11 To increase 
diagnosis and treatment, the National 
Institute for Health and Care Excellence 
(NICE) recommends implementing cost-
effective interventions to increase case finding 
in primary care;12 however, robust evidence is 
lacking, and case finding and treatment rates 
in many sites are low.13 
The Hepatitis C Assessment Through to 
Treatment (HepCATT) trial was conducted 
to assess whether a complex intervention 
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Abstract
Background
Hepatitis C virus (HCV) infection is a key cause of 
liver disease but can be cured in more than 95% 
of patients. Around 70 000 people in England 
may have undiagnosed HCV infection and many 
more will not have been treated. Interventions 
to increase case-finding in primary care are 
likely to be cost-effective; however, evidence of 
effective interventions is lacking. The Hepatitis C 
Assessment Through to Treatment (HepCATT) 
trial assessed whether a complex intervention 
in primary care could increase case-finding, 
testing, and treatment of HCV.
Aim
To investigate the feasibility and acceptability of 
the HepCATT intervention.
Design and setting
A qualitative study with primary care practice 
staff from practices in the south west of 
England taking part in the HepCATT trial.
Method
Semi-structured interviews were carried out 
with GPs, nurses, and practice staff to ascertain 
their views of the HepCATT intervention at least 
1 month after implementing the intervention in 
their practice. Normalisation process theory, 
which outlines the social processes involved in 
intervention implementation, informed thematic 
data analysis.
Results
Participants appreciated the HepCATT 
intervention for increasing knowledge and 
awareness of HCV. Although some initial technical 
difficulties were reported, participants saw the 
benefits of using the audit tool to systematically 
identify patients with HCV infection risk factors 
and found it straightforward to use. Participants 
valued the opportunity to discuss HCV testing 
with patients, especially those who may not 
have been previously aware of HCV risk. Future 
implementation should consider fully integrating 
software systems and additional resources to 
screen patient lists and conduct tests. 
Conclusion
When supported by a complex intervention, 
primary care can play a crucial role in 
identifying and caring for patients with HCV 
infection, to help stem the HCV epidemic, and 
prevent HCV-related illness. 
Keywords
hepatitis C; primary care; qualitative research; 
randomised controlled trial; screening.
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in primary care could increase the 
identification and treatment of HCV-infected 
patients compared with usual care.14 The 
HepCATT intervention, following NICE 
recommendations, consisted of training 
practice staff about HCV; providing patients 
with information about HCV; and use of an 
electronic patient record algorithm to identify 
patients with HCV infection risk factors or 
patients who had been previously diagnosed 
and not referred for treatment. During the 
trial, 2071 (16%) of patients identified in the 
intervention practices and 1163 (10%) in 
the control practices were tested for HCV, 
giving an overall intervention effect as an 
adjusted risk ratio of 1.59 (95% CI = 1.21 to 
2.08, P<0.001).15 Intervention practices had 
a greater yield of positive antibody tests 
compared with control practices (6.2% versus 
4.2%; rate ratio 1.42; 95% CI = 0.95 to 2.13), 
and the intervention was demonstrated 
to be highly cost-effective for the NHS.15 
Recommendations have been made by 
the trial team to implement the HepCATT 
intervention across the UK.
This article describes the HepCATT trial 
nested qualitative study, which aimed to 
investigate practice staff members’ views 
and experiences of intervention acceptability, 
and the facilitators and challenges to wider 
implementation of the intervention.
METHOD
Study design 
The HepCATT trial was a pragmatic two-
armed practice-level cluster randomised 
controlled trial in 45 primary care practices 
(22 intervention and 23 control) in the south 
west of England. Practices were randomised 
to either control (usual care) or intervention. 
The intervention comprised:
• online HCV educational resources 
(Royal College of General Practitioners 
e-learning module — Hepatitis C: 
Enhancing Prevention, Testing and Care) 
and 1-hour face-to-face staff training on 
the epidemiology, diagnosis, management 
of HCV infection, and trial processes;
• patient posters and leaflets explaining 
HCV risk factors and treatment options in 
practice waiting rooms; and
• Audit+ software (Informatica Systems Ltd) 
integrated into practice electronic patient 
record systems and used to identify 
patients with risk factors for HCV infection 
or patients who had been diagnosed 
>1 year previously without a referral for 
treatment.14
Patients identified by the audit tool were 
invited by letter/email (and followed up by 
telephone, email, or text) for an HCV test, 
and automatically flagged by the software 
by creating on-screen pop-ups to encourage 
opportunistic testing if the patient attended a 
consultation. 
Semi-structured interviews were 
conducted with staff in intervention practices 
involved in implementing the intervention 
to investigate their views and experiences 
of the intervention; the acceptability and 
feasibility of the intervention; the impact on 
working practice; and attitudes to future 
implementation. 
Sampling and recruitment 
Purposive sampling was used to capture 
maximum variation in views and experiences, 
and to reflect a range of practices (in relation 
to size and location based on socioeconomic 
deprivation), and staff (in relation to 
professional roles). The socioeconomic status 
of practice populations was estimated using 
the Index of Multiple Deprivation decile.16 Staff 
from all 22 intervention practices were invited 
to participate in an interview after delivering 
the intervention for ≥1 month via email or 
telephone. Sample size was informed by 
the concept of ‘information power’,17 with 
analysis and sampling conducted in parallel 
and continuous assessment of the suitability 
of the information within the sample with 
regard to study objectives.
Data collection
Telephone Interviews were conducted by 
an experienced social science researcher. 
How this fits in 
Although the Royal College of General 
Practitioners and the National Institute 
for Health and Care Excellence provide 
guidance for GPs on testing for hepatitis C, 
research suggests that the current practice 
of case-finding, testing, and treatment 
is not effective. This study examined 
the implementation of the HepCATT 
(Hepatitis C Assessment Through to 
Treatment) trial complex intervention, 
which consists of training practice staff; 
providing patient HCV posters and leaflets; 
and using an electronic patient record 
algorithm for proactive case-finding of 
patients with HCV infection risk factors or 
patients diagnosed >1 year previously with 
no evidence of referral for treatment. The 
intervention was found to be feasible and 
acceptable to staff, and could be effective 
in supporting primary care to follow 
hepatitis C infection testing and treatment 
guidelines.
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Audio-recorded verbal consent was gained 
before the interviews, which lasted between 
12 and 47 minutes, with an average time of 
25 minutes. A flexible topic guide was used 
to assist questioning but allow participants 
to introduce new issues (Box 1). 
Data analysis
Interviews were audio-recorded, 
transcribed, anonymised, imported to NVivo 
(version 10), and thematically analysed.18 
Transcripts were coded inductively to 
establish an initial analysis framework and 
three researchers coded a subset of two 
transcripts; discrepancies were discussed 
to ensure a coding consensus and 
maximise rigour.19 The four normalisation 
process theory constructs20 were used to 
further develop themes across the dataset. 
Normalisation process theory proposes 
that implementation of interventions is 
dependent on staff fulfilling four criteria 
(Box 2).20 Emergent analysis was discussed 
in multidisciplinary trial management 
group meetings to ensure that findings 
were trustworthy and credible.
RESULTS
Fourteen healthcare professionals (HCPs) 
(seven GPs, three nurses, and four practice 
staff) were interviewed from across 12 
practices — five in areas of high deprivation 
(Table 1). Findings are presented for 
each of the normalisation process theory 
constructs, illustrated with anonymised 
verbatim quotes.
1. Coherence (sense making)
All HCPs described their practice of HCV 
testing before HepCATT as opportunistic and 
sporadic, testing patients with a history of 
drug dependency, abnormal liver function, 
and/or other infections such as HIV or 
hepatitis B. Only two HCPs described other 
HCV infection risk factors, such as blood 
transfusions given abroad, a family member 
with HCV, or high-risk sexual activity: 
‘If somebody came, you know, and we found 
they had HIV, we definitely tested. Um, I think 
if they had a hepatitis B they were tested as 
well but I don’t think it was routinely picked 
up on for anybody else.’ (Site 17, Nurse)
Participants understood the relevance 
of the intervention and valued its perceived 
impact. Initial engagement was led by an 
interest in finding out whether there were 
patients with HCV infection risk factors 
at their practice who had not yet been 
previously identified:
‘I was interested to see whether we would 
have anybody, because my first thoughts 
were was “oh, we will be fine because you 
know [doctor] does it and the drugs workers 
do it all” … I thought “oh, maybe we have 
missed people but we will wait and see”.’ 
(Site 6, GP)
‘I think it would be a sensible thing to do 
because I think that if we can diagnose 
Box 1. Interview discussion topic guide
• Existing HCV identification practice before HepCATT intervention
• Acceptability of the intervention
 – Experiences of using the software
 – Views on opportunistic prompts
• Feasibility of the intervention
 – Appropriateness of patients identified
 – Difficulties experienced with offering the test
 – Support needs
• Approaching patients for testing opportunistically
 – Patient information support needs
 – Perceived patient views about being approached for testing
• Future implementation of the intervention in primary care
 – Improvements to intervention
 – Potential barriers
 – Recommendations for roll-out of the intervention
HCV = hepatitis C virus. HepCATT = Hepatitis C Assessment Through to Treatment
Box 2. Normalisation process theory criteria
1. Coherence: sense making — understanding and opinion of the intervention purpose
2. Cognitive participation: buy-in — engagement with the intervention
3. Collective action: the work of putting the intervention into operation
4. Reflexive monitoring: appraisal of the intervention
Table 1. Participant characteristics
 Practices
 Deprivation decilea Patient population
Participants n High Low <9000 9000–13 000 >13 000
GPs 7 2 5 4 1 2
Nurses 3 0 3 0 2 1
Practice managers 1 1 0 0 1 0
Information technology/  3 2 1 1 2 0 
administrators
Total 14 5 9 5 6 3
aIndex of Multiple Deprivation.16
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people with hepatitis C earlier then 
potentially we can reduce their risk of 
becoming cirrhotic.’ (Site 9, GP)
2. Cognitive participation (buy-in)
Participants valued the training for 
enhancing HCV awareness and increasing 
knowledge, particularly in practices with 
lower levels of patients with existing HCV. 
Even those with previous experience of HCV 
believed the training had expanded their 
knowledge of risk factors for HCV infection 
and who to target for testing:
‘Hepatitis C was something I was aware of 
anyway, perhaps more so than other GPs 
because of my work as a drugs lead … 
certainly that was always a population that 
I’m aware that we should be screening … 
but I think that the way HepCATT worked 
was potentially broadening out that … it 
was a broader remit to think of hepatitis C.’ 
(Site 11, GP)
‘I don’t think it was on people’s radar 
particularly because there’s so many other 
things going on … the doctors all said “you 
know, we hadn’t even thought about that”.’ 
(Site 18, Nurse)
The training itself acted as a prompt for 
opportunistic testing:
‘I think having the discussion at the 
beginning of the trial to raise awareness 
and remind people about the risk factors 
of hepatitis C probably led to some people 
offering the test perhaps where they 
wouldn’t have done.’ (Site 11, GP)
3. Collective action (putting HepCATT into 
operation)
Audit tool. Some practices encountered 'a 
few teething problems' (Site 11, GP) with 
setting up the audit tool, compatibility issues, 
and not always having the necessary time 
and resources; however, with support from 
the trial team and the software company, 
difficulties were resolved, and practices 
went on to use the audit tool without issue:
‘It took a bit of getting used to but I felt like 
we had support to find our way around it 
… you had to take the time just to focus 
on it and get used to it, but it worked 
fine when you were familiar with it … that 
[support from trial team] helped a lot.’ 
(Site 2, Administrator)
Participants saw the benefits of identifying 
patients using the audit tool and most 
liked that it was ‘straightforward’ to use 
and helpful in ‘identifying the right people’. 
(Site 2, Administrator):
‘I think it’s fairly robust at identifying the 
patient that is at risk.’ (Site 9, GP)
Screening lists of patients with HCV 
infection risk factors produced by the 
audit tool were perceived to be mostly 
appropriate. Although the algorithm 
automatically excluded certain patients 
(such as those on opioid patches for 
pain relief or who were terminally ill), 
issues arose in some practices with 
inconsistencies in medical record coding 
leading to inappropriate patients being 
identified. This was particularly pertinent 
to how drug users were categorised. This 
meant that, for some, the benefits of using 
the Audit+ software were offset by additional 
resource and time needed to screen lists. To 
reduce GP workload, in some practices 
administrators or nurses reviewed patient 
lists before GP screening:
‘I think the only problem was about the 
codes that we’d used … we had one partner 
in particular who tended to code this little 
lady who couldn’t get off her sleeping 
tablets as drug dependent and that was a 
problem for us, because that’s flagged up 
unnecessary ones.’ (Site 5, GP)
‘She [administrator] would pull off the lists 
and have a quick scan … highlight the ones 
she thinks aren’t right … then I look through 
it … so 10 sets of notes … I would pull the 
notes up, quickly have a look to see if there 
is anything that I mean is palliative care, 
they have just had a consultation that hasn’t 
been coded.’ (Site 6, GP)
HCV testing via invite letters. Some 
participants were initially concerned about 
the resources needed to implement the 
intervention. Resource concerns were 
threefold: first, to manage the mail-out 
to identified patients; second, to deal with 
patient queries; and, third, to conduct the 
HCV tests. To address this, practices sent 
letters out in batches:
‘We haven’t sent out the whole lot, we would 
only do like 20 at a time, so we didn’t want 
20 people to ring up saying they wanted a 
test, that would have had a big impact on 
the practice, but it didn’t turn out to be the 
case.’ (Site 6, GP)
Participants also worried about 
disappointing patients by not being able to 
schedule a test promptly. They believed this 
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would result in patients not trying to book a 
test at a later date. Therefore, one practice 
appointed a dedicated nurse to liaise with 
patients and conduct tests:
‘We don’t want them [patients] to be 
disappointed, because if they ring up and 
we say “oh, that’s in a month’s time” … they 
won’t be interested.’ (Site 6, GP) 
A few practices commented that 
engaging patients with a history of injecting 
drug use was challenging because they 
often did not respond to HCV testing invite 
letters and the practice had to ‘chase up 
the patients’ (Site 18, Nurse); however, most 
HCPs described that patients were happy to 
be approached and they did not receive any 
negative feedback:
‘We haven’t had any negative erm 
comments from patients saying “Why have 
I been picked?” or anything like that … if the 
doctors have identified more risk for the 
letter, then obviously, I go through it with 
them and explain why their name has come 
up. And they’re very understanding of why 
their name has been picked up.’ (Site 13, 
Nurse)
A few HCPs described being cautious 
about approaching patients for testing with 
risk factors other than injecting drug use, 
such as organ transplants or past blood 
transfusions, because they did not want to 
scare them, but the intervention allowed for 
testing options to be discussed:
‘But it [intervention] kind of opened up the 
conversation with them … we had to be very 
careful, we didn’t want to scare patients and 
the ones that probably fell into that ball park 
were the ones who’d had transfusions or 
some sort of procedure where they might 
be at risk but a long time ago. That was a 
little bit difficult, but once we had explained 
it to them, why it was a problem and why it 
might be a risk and they kind of were happy 
to then go ahead.’ (Site 5, GP)
Only one practice described a negative 
response from a small number of HIV-
positive patients, because they felt they 
were being stigmatised and they were 
already screened regularly for HCV at the 
local hospital:
‘Some of our HIV patients, I mean two or 
three, were a little bit upset and also you 
know when I went into their records, they’re 
all seen regularly at hospital and they do 
have regular Hep C tests there.’ (Site 11, 
Administrator)
Opportunistic HCV testing via ‘pop-
up’ computer screen alerts. Because 
of the busy nature of primary care, the 
computer screen alerts or pop-ups to 
opportunistically identify patients with HCV 
risk factors during routine consultations 
were commonly not welcomed or used by 
GPs. Patients often presented with complex 
needs and immediate clinical problems 
were prioritised over discussing HCV risk 
and testing given the limited consultation 
time. Participants also spoke of pop-up 
fatigue, of having too many screen pop-ups 
when dealing with a patient and therefore 
the impact of the alerts becoming diluted. 
Using the screen pop-ups was also made 
more challenging by the requirement for 
GPs to log in to the Audit+ software to 
activate them, which they often forgot or 
opted not to do:
‘Just remembering to switch it on in the 
morning was probably the biggest issue 
… but then I suspect that probably GPs 
because of the number of pop-ups it fired 
at you would have ignored it or try to switch 
it off at some point.’ (Site 11, GP)
‘We recognised that people were just a bit 
swamped and couldn’t factor that into their 
10-minute appointment.’ (Site 5, GP)
Although GPs did not welcome the screen 
pop-ups, some nurses thought they could 
be useful to keep HCV testing on people’s 
‘radar’:
‘I’m always very happy with the opportunistic 
testing because if I’ve got a pop-up box it’s 
fantastic. I will see it and speak to the 
patients about it.’ (Site 18, Nurse)
4. Reflexive monitoring (appraisal of 
HepCATT intervention)
When appraising the intervention and 
making recommendations for future 
implementation, participants suggested 
streamlining information technology 
systems. Integrating the algorithm and 
screen pop-up systems within existing 
electronic patient record systems (for 
example, EMIS) would remove the need 
for HCPs to additionally log in to the Audit+ 
software:
‘Trying to make that alert part of EMIS 
might be better, because having a separate 
bit of software … it did rely on each doctor 
logging in every morning and so perhaps 
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having a prompt in EMIS might be more 
reliable … as we tend to use prompts in 
EMIS more.’ (Site 10, GP)
The record search algorithm was based 
on a large number of Read codes and 
risk factors were not weighted. A few 
participants suggested refining the search 
algorithm so it could be tailored by the 
practice to focus on more high-risk patients 
and reduce the number of inappropriate 
patients identified. This would in turn reduce 
practice staff workload in screening lists of 
patients identified and sending invites, and 
would allow realistic financial planning:
‘Being a bit more focused on the patients 
who are more at risk … it felt like it was 
literally picking everyone up who might have 
the minutest risk of hepatitis … and it didn’t 
always feel appropriate … maybe it felt like 
the search could be narrowed down a bit 
than perhaps using a too broad a remit.’ 
(Site 11, GP)
‘We send out a lot of letters for a minimal 
response … when there’s more acute 
patients that could be identified … whether 
that’s something in the audit or the coding 
… that identifies the high-risk rather than 
medium-risk patients.’ (Site 13, Nurse)
Some participants suggested changing 
the wording of the HCV testing invite letter 
to alleviate staff concerns regarding sending 
the letters to certain patient groups:
‘If you have, you know, something like 
“please don’t be offended but we are just 
sending letters out to anybody who’s had a 
Hep C blood test in the last 20–25 years” … 
we did have to be sort of careful if somebody 
might have had one for fertility blood test 
and they maybe now had a new partner, 
you know, whether picked up that letter 
it’s, you know, they might be thinking “oh, 
you know, why have you got this?”.’ (Site 11, 
Administrator)
Implementing HepCATT in more practices 
could be enabled by increasing activities 
to raise patient and HCP awareness and 
acceptance of HCV and testing. A public 
health campaign and ongoing clinician 
training were suggested:
‘My awareness will gradually fade.’ (Site 14, 
GP) 
‘I think it’s the patients accepting it … but 
then that’s education of the public isn’t it? 
Everybody knows if you have bleeding down 
below, you have to go and see your doctor, if 
you cough up blood, go and see your doctor 
as there has been big public campaigns … 
but as far as I’m aware, I haven’t seen them 
[hepatitis C campaigns].’ (Site 6, GP)
Some participants suggested additional 
resources would be required for practices 
to implement the intervention:
‘If you’re asking more practices to do more 
work then practices need to be funded to do 
more work, you can’t just expect surgeries 
to take on more work. You get people 
phoning and speaking to the receptionist 
about the letter they received, you get 
people making appointments, you have the 
cost of the blood test … they might need an 




The HepCATT intervention was valued 
by primary care staff for enhancing 
systematic identification of patients with 
HCV infection with the potential to benefit 
from treatment, compared with previous 
opportunistic and sporadic HCV testing. 
HepCATT training enhanced awareness 
of HCV and improved knowledge of HCV 
infection risk factors. Although there were 
initial teething problems with setting up 
the audit tool in some practices, most 
staff found it straightforward and helpful, 
and valued having a comprehensive list 
of patients to target for testing. Extra 
resources were required to screen lists and 
to conduct tests, and practices often drew 
on the expertise of nurses to reduce GP 
workload. Fees for running the algorithm 
and contingency staff management to 
conduct tests should be considered in 
wider implementation of the intervention. 
Staff valued the opportunity to discuss HCV 
testing with patients, especially those who 
may not have been previously aware of HCV 
risk; however, practices need to be cautious 
not to additionally stigmatise patients with 
conditions such as HIV, particularly those 
who may receive regular screening for HCV 
in secondary care. Although the algorithm 
excluded patients who had been tested 
for HCV within the previous 12 months, it 
relied on patient record data. Therefore, 
if a patient had recently received an HCV 
test in secondary care, test results may not 
have been apparent on patient records at 
the time of the record search. As with any 
algorithm-based intervention, the quality 
and completeness of medical records are 
critical for its effectiveness. 
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When considering further use of the 
intervention, participants suggested refining 
the search algorithm to weight risk factors 
to reduce the number of inappropriate 
patients identified. Participants also 
recommended fully integrating information 
technology systems, especially computer 
screen pop-up software with electronic 
patient record systems. Views on the 
value of screen pop-up prompts were 
mixed, with some GPs highlighting ‘pop-
up fatigue’, while some nurses valued 
reminders to consider HCV testing. Pop-up 
alerts have been found to be beneficial in 
influencing clinicians’ behaviour;21 however, 
the danger of electronic patient record-
based alerts overload, producing ‘pop-up 
fatigue’, is a common phenomenon.22,23 
Future implementation of HepCATT should 
ensure that on-screen pop-ups are tailored 
to ensure a balance between adequate 
alerting and burden. 
Strengths and limitations
Participants were recruited using a 
diverse sample of practices, GPs, practice 
nurses, and information technology and/
or administration staff to ensure that all 
aspects of the intervention were captured, 
including software installation and use, case 
finding, patient consultation, and testing. 
Analysis demonstrated a high degree of 
similarity between views and experiences, 
suggesting acceptability across practices 
serving different communities. The use of 
normalisation process theory to inform 
analysis allowed for examination of issues 
with both the intervention design and its 
implementation. A study limitation is that 
no interviews were conducted with patients, 
which should be taken into consideration 
when interpreting the results. Although 
HCPs did discuss how the intervention was 
received by patients, which provided some 
insight into patients’ views, there were no 
problems raised by HCPs except for a few 
patients living with HIV. These patients, 
because of delays with previous HCV test 
results from secondary care, should have 
been excluded from screening lists. 
Comparison with existing literature
HepCATT trial findings demonstrated an 
effective and cost-effective intervention.15 
Although the effect size was modest, the 
intervention is very low cost to implement. 
Previous research has suggested that a 
high proportion of patients at risk of HCV 
are not being tested in primary care as a 
result of clinicians not remembering to test 
patients with risk factors, and not being able 
to quickly and reliably determine HCV risk 
and status from EMIS coding.10 The current 
study demonstrates that HepCATT can 
overcome these issues, with staff valuing 
the intervention as a straightforward means 
of identifying at-risk patients and providing 
an opportunity to discuss HCV testing. As 
HCV infection is usually asymptomatic, 
staff welcomed the HepCATT intervention 
proactive case finding based on HCV risk 
factors. The HepCATT intervention aligns 
with the ‘new service model for the 
21st century’ aspiration of the NHS Long 
Term Plan to be more proactive in providing 
services to enable individuals ‘to take more 
control of how they manage their physical 
and mental wellbeing’.24 As other HCV 
primary care interventions have found,25 the 
current study indicated resource concerns 
for proactive case finding and increasing HCV 
testing; however, the findings demonstrate 
that nurses might be considered to alleviate 
increased GP workload. Previous research 
has also identified nursing support as a 
critical facilitator to increasing primary care 
HCV testing and as effective in supporting 
adherence to HCV testing and treatment 
guidelines.26
Implications for practice
With adequate resources and technology, 
primary care can play an important role 
in identifying patients with HCV infection 
who have the potential to benefit from 
treatment. While there needs to be a 
multipronged approach to increase HCV 
testing in a range of settings, including 
prisons and drug treatment centres, the 
cost-effective HepCATT intervention 
provides primary care with a range of tools 
to improve the identification and care of 
patients with HCV infection, and prevent 
HCV-related illness. This could help the UK 
to reach the WHO target of 90% of infected 
people knowing their status by 2030 and 
help to stem the HCV epidemic, reducing 
the risk of morbidity, mortality, and onward 
transmission.11 
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